Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Castle Biosciences stock

Own Castle Biosciences stock in just a few minutes.

Castle Biosciences, Inc is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Castle Biosciences employs 199 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Castle Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CSTL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Castle Biosciences share price

Use our graph to track the performance of CSTL stocks over time.

Castle Biosciences shares at a glance

Information last updated 2021-04-29.
52-week range$26.13 - $107.69
50-day moving average $66.46
200-day moving average $65.56
Wall St. target price$85.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.14

Buy Castle Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Castle Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Castle Biosciences under- or over-valued?

Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Castle Biosciences's EBITDA

Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.

The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.

Castle Biosciences financials

Revenue TTM $62.6 million
Gross profit TTM $53 million
Return on assets TTM -1.88%
Return on equity TTM -4.11%
Profit margin -16.42%
Book value $4.82
Market capitalisation $1.7 billion

TTM: trailing 12 months

Shorting Castle Biosciences shares

There are currently 2.2 million Castle Biosciences shares held short by investors – that's known as Castle Biosciences's "short interest". This figure is 7.1% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Castle Biosciences shares can be evaluated.

Castle Biosciences's "short interest ratio" (SIR)

Castle Biosciences's "short interest ratio" (SIR) is the quantity of Castle Biosciences shares currently shorted divided by the average quantity of Castle Biosciences shares traded daily (recently around 322318.32844575). Castle Biosciences's SIR currently stands at 6.82. In other words for every 100,000 Castle Biosciences shares traded daily on the market, roughly 6820 shares are currently held short.

However Castle Biosciences's short interest can also be evaluated against the total number of Castle Biosciences shares, or, against the total number of tradable Castle Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Castle Biosciences's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Castle Biosciences shares in existence, roughly 90 shares are currently held short) or 0.1314% of the tradable shares (for every 100,000 tradable Castle Biosciences shares, roughly 131 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Castle Biosciences.

Find out more about how you can short Castle Biosciences stock.

Castle Biosciences share dividends

We're not expecting Castle Biosciences to pay a dividend over the next 12 months.

Castle Biosciences overview

Castle Biosciences, Inc. , a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site